$16.8 M

CYCC Mkt cap, 22-Sept-2020
Cyclacel Pharmaceuticals Net income (Q2, 2020)-2.2 M
Cyclacel Pharmaceuticals EBIT (Q2, 2020)-2.5 M
Cyclacel Pharmaceuticals Cash, 30-Jun-202025.3 M
Cyclacel Pharmaceuticals EV-7.4 M

Cyclacel Pharmaceuticals Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

168.0k164.0k161.0k146.0k38.0k212.0k264.0k309.0k396.0k356.0k735.0k512.0k296.0k715.0k139.0k205.0k

Cost of goods sold

72.0k95.0k94.0k89.0k

Gross profit

96.0k69.0k67.0k57.0k

Gross profit Margin, %

57%42%42%39%

R&D expense

1.9m2.1m1.3m1.7m1.5m1.6m2.6m4.6m4.3m4.5m5.0m4.3m2.6m2.9m2.5m2.6m2.4m1.3m1.2m958.0k798.0k1.2m1.2m1.0m1.2m1.1m1.1m1.2m

General and administrative expense

2.0m2.1m2.0m2.4m2.0m2.7m1.8m1.5m1.5m1.4m1.4m1.5m1.3m1.2m1.4m1.3m1.3m1.4m1.3m1.2m1.4m1.3m1.3m1.2m1.2m1.3m1.3m1.3m

Operating expense total

3.9m4.1m3.3m4.1m3.6m4.3m4.4m6.1m5.8m5.9m6.4m5.8m3.9m4.1m3.9m4.0m3.7m2.7m2.5m2.1m2.2m2.5m2.5m2.2m2.3m2.3m2.4m2.5m

EBIT

(3.8m)(4.0m)(3.3m)(4.0m)(3.5m)(4.1m)(4.2m)(5.8m)(5.4m)(5.6m)(5.7m)(5.3m)(3.6m)(3.4m)(3.7m)(3.8m)(3.5m)(2.7m)(2.5m)(2.1m)(2.2m)(2.5m)(2.5m)(2.2m)(2.3m)(2.3m)(2.4m)(2.5m)

EBIT margin, %

(2260%)(2468%)(2035%)(2747%)(9268%)(1911%)(1573%)(1875%)(1366%)(1566%)(771%)(1035%)(1222%)(475%)(2694%)(1696%)

Interest expense

119.0k477.0k153.0k306.0k50.0k695.0k5.4m49.0k36.0k60.0k9.0k377.0k135.0k207.0k210.0k169.0k77.0k12.0k34.0k36.0k69.0k111.0k86.0k94.0k247.0k174.0k

Interest income

13.0k9.0k6.0k6.0k5.0k1.0k3.0k8.0k1.0k1.0k3.0k1.0k2.0k2.0k10.0k13.0k8.0k12.0k18.0k30.0k69.0k84.0k85.0k79.0k56.0k42.0k28.0k4.0k

Pre tax profit

(3.7m)(3.6m)(3.1m)(3.7m)(3.6m)(3.4m)1.2m(5.7m)(5.4m)(5.6m)(5.7m)(5.7m)(3.8m)(3.2m)(3.5m)(3.6m)(3.4m)(1.9m)(2.5m)(2.1m)(1.5m)(2.4m)(2.4m)(2.1m)(2.1m)(2.2m)(1.5m)(2.5m)

Income tax expense

(126.0k)(126.0k)(168.0k)(127.0k)(419.0k)(258.0k)(230.0k)(730.0k)(569.0k)(816.0k)(750.0k)(763.0k)(405.0k)(478.0k)(493.0k)(626.0k)(454.0k)(306.0k)(268.0k)(219.0k)(182.0k)(502.0k)(301.0k)(268.0k)(307.0k)(273.0k)(290.0k)(286.0k)

Net Income

(3.6m)(3.4m)(3.0m)(3.6m)(1.9m)(3.1m)1.5m(5.0m)(4.9m)(4.8m)(4.9m)(4.9m)(3.3m)(2.7m)(3.0m)(3.0m)(2.9m)(1.6m)(2.2m)(1.9m)(1.3m)(1.9m)(2.1m)(1.8m)(1.8m)(1.9m)(1.2m)(2.2m)

Cyclacel Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

24.4m16.4m31.1m24.2m20.4m16.5m23.9m17.5m11.9m

Prepaid Expenses

1.2m1.6m3.4m4.6m4.1m2.1m2.3m2.1m

Inventories

182.0k

Current Assets

25.8m18.9m35.2m29.0m24.6m19.6m26.0m19.8m14.0m

PP&E

167.0k129.0k275.0k387.0k198.0k45.0k29.0k36.0k27.0k

Total Assets

26.0m19.4m35.5m29.4m24.8m19.7m26.0m19.8m15.3m

Accounts Payable

1.8m2.3m2.5m2.8m1.9m2.5m1.6m2.7m890.0k

Current Liabilities

6.5m9.3m7.5m7.5m5.8m5.3m4.1m4.5m2.4m

Long-term debt

1.2m

Total Debt

1.2m

Total Liabilities

6.5m9.3m7.5m7.7m5.9m5.4m4.2m4.6m3.6m

Common Stock

54.0k9.0k19.0k23.0k35.0k12.0k12.0k17.0k

Preferred Stock

1.0k1.0k

Additional Paid-in Capital

276.5m280.2m317.5m331.0m342.6m350.1m365.1m365.8m370.1m

Retained Earnings

(257.1m)(270.2m)(289.4m)(308.8m)(323.2m)(335.0m)(342.5m)(349.8m)(357.6m)

Total Equity

19.5m10.0m28.0m21.7m18.8m14.3m21.8m15.3m11.7m

Financial Leverage

1.3 x1.9 x1.3 x1.4 x1.3 x1.4 x1.2 x1.3 x1.3 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

20.6m27.7m23.6m20.0m17.8m14.1m33.7m34.5m28.2m33.5m26.7m29.4m26.9m22.7m17.1m15.9m18.0m12.7m13.6m26.0m21.7m19.8m19.0m17.9m15.2m13.0m8.9m25.3m

Accounts Receivable

45.0k

Prepaid Expenses

1.7m941.0k1.4m1.6m1.2m2.1m2.7m2.4m4.7m3.4m4.2m5.5m3.5m4.0m4.1m2.8m4.5m4.3m2.5m1.8m3.0m2.9m1.7m2.2m3.0m2.9m2.9m2.6m

Inventories

147.0k165.0k109.0k50.0k

Current Assets

22.4m28.8m25.2m21.7m20.0m17.0m37.2m37.7m33.5m37.3m31.2m35.0m30.5m26.8m21.3m18.8m22.6m17.0m16.1m27.8m24.7m22.7m20.7m20.1m18.2m15.8m11.8m27.9m

PP&E

246.0k165.0k166.0k149.0k140.0k184.0k169.0k174.0k285.0k305.0k454.0k333.0k309.0k255.0k151.0k109.0k73.0k39.0k32.0k34.0k45.0k43.0k38.0k33.0k29.0k28.0k25.0k20.0k

Total Assets

22.7m28.9m25.3m21.8m20.5m17.5m37.5m38.0m33.8m37.6m31.6m35.4m30.8m27.0m21.5m18.9m22.7m17.1m16.1m27.9m24.8m22.7m20.7m21.5m19.5m17.1m13.0m29.2m

Accounts Payable

1.1m1.1m1.1m1.5m1.6m2.8m2.4m2.4m4.7m4.5m2.2m4.0m2.6m1.6m1.6m1.9m2.0m1.7m2.0m2.0m1.9m1.7m1.4m1.3m1.1m887.0k250.0k342.0k

Current Liabilities

6.0m5.9m6.8m6.7m7.3m7.3m6.6m9.0m8.8m7.8m6.8m8.1m6.5m5.3m5.4m5.6m5.6m4.1m4.3m4.3m4.3m4.0m4.0m2.5m2.5m2.1m1.5m1.5m

Long-term debt

1.5m1.2m1.2m1.1m1.1m

Total Debt

1.5m1.2m1.2m1.1m1.1m

Total Liabilities

6.0m5.9m6.8m6.7m7.3m7.3m6.6m9.0m8.8m8.0m7.0m8.3m6.7m5.4m5.6m5.7m5.7m4.3m4.4m4.4m4.4m4.1m4.1m4.0m3.7m3.2m2.6m2.6m

Common Stock

47.0k55.0k59.0k59.0k8.0k11.0k17.0k18.0k20.0k23.0k23.0k34.0k34.0k34.0k35.0k3.0k4.0k4.0k4.0k12.0k12.0k12.0k12.0k17.0k17.0k1.0k5.0k

Preferred Stock

1.0k1.0k1.0k1.0k1.0k

Additional Paid-in Capital

266.5m276.3m278.4m278.5m278.7m292.1m311.1m315.0m319.4m328.8m328.9m341.4m341.5m341.9m342.8m343.2m349.9m350.2m351.1m364.8m365.1m365.1m365.2m370.0m369.9m370.1m370.2m388.5m

Retained Earnings

(250.0m)(253.4m)(260.0m)(263.6m)(265.5m)(281.7m)(280.2m)(285.9m)(294.3m)(299.1m)(304.0m)(313.7m)(317.1m)(319.8m)(326.3m)(329.3m)(332.2m)(336.6m)(338.8m)(340.6m)(343.9m)(345.7m)(347.8m)(351.6m)(353.4m)(355.3m)(358.8m)(361.0m)

Total Equity

16.7m23.0m18.5m15.1m13.2m10.2m30.9m29.0m25.0m29.6m24.6m27.0m24.1m21.6m15.9m13.2m16.9m12.8m11.6m23.5m20.4m18.6m16.6m17.6m15.7m13.9m10.4m26.6m

Financial Leverage

1.4 x1.3 x1.4 x1.4 x1.6 x1.7 x1.2 x1.3 x1.4 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.4 x1.3 x1.3 x1.4 x1.2 x1.2 x1.2 x1.2 x1.2 x1.2 x1.2 x1.2 x1.1 x

Cyclacel Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(8.1m)(11.6m)(3.0m)(6.5m)(8.4m)(3.1m)(1.6m)(6.6m)(4.9m)(9.7m)(14.6m)(4.9m)(8.3m)(11.0m)(3.0m)(6.0m)(9.0m)(1.6m)(3.7m)(5.6m)(1.3m)(3.2m)(5.3m)(1.8m)(3.6m)(5.5m)(1.2m)(3.4m)

Depreciation and Amortization

172.0k250.0k15.0k30.0k45.0k26.0k36.0k58.0k23.0k46.0k115.0k52.0k102.0k157.0k42.0k75.0k109.0k9.0k17.0k25.0k7.0k15.0k22.0k6.0k10.0k15.0k5.0k10.0k

Accounts Payable

(482.0k)162.0k(807.0k)(709.0k)(220.0k)(1.3m)(1.5m)837.0k1.2m313.0k(403.0k)887.0k(1.1m)(2.1m)(187.0k)316.0k464.0k(1.2m)(1.2m)(1.3m)(2.0k)(63.0k)8.0k(689.0k)(2.1m)(2.4m)(799.0k)(798.0k)

Cash From Operating Activities

(8.5m)(10.7m)(3.8m)(7.5m)(9.6m)(5.4m)(10.7m)(12.8m)(4.7m)(8.8m)(15.0m)(4.9m)(7.7m)(11.8m)(3.1m)(4.2m)(7.1m)(3.8m)(4.0m)(5.3m)(2.1m)(3.9m)(4.7m)(3.7m)(6.3m)(8.3m)(2.8m)(4.7m)

Purchases of PP&E

(6.0k)(9.0k)(10.0k)(12.0k)(92.0k)(92.0k)(99.0k)(31.0k)(65.0k)(302.0k)(14.0k)(22.0k)(32.0k)(2.0k)(2.0k)(11.0k)(22.0k)(31.0k)(33.0k)(2.0k)(3.0k)(7.0k)(4.0k)(4.0k)

Cash From Investing Activities

(6.0k)15.0k52.0k50.0k40.0k5.7m5.7m65.0k127.0k(14.0k)9.0k1.0k(9.0k)(2.0k)(2.0k)(11.0k)(22.0k)(31.0k)(33.0k)27.0k26.0k22.0k(4.0k)(4.0k)

Dividends Paid

(364.0k)(364.0k)(129.0k)(192.0k)(255.0k)(50.0k)(100.0k)(150.0k)(50.0k)(100.0k)(150.0k)(50.0k)(100.0k)(150.0k)(50.0k)(101.0k)(151.0k)(50.0k)(101.0k)(151.0k)(50.0k)(101.0k)(151.0k)(50.0k)(101.0k)

Cash From Financing Activities

(441.0k)8.9m2.9m2.9m2.9m3.3m22.3m25.4m1.6m10.9m10.8m10.4m10.3m10.4m(50.0k)54.0k5.1m36.0k962.0k14.6m(50.0k)(101.0k)(151.0k)4.1m4.0m3.9m(50.0k)18.2m

Net Change in Cash

(8.9m)(1.8m)(809.0k)(4.5m)(6.6m)(2.3m)17.3m18.1m(3.0m)2.3m(4.4m)5.2m2.7m(1.5m)(3.3m)(4.5m)(2.4m)(3.8m)(2.9m)9.5m(2.2m)(4.1m)(4.9m)430.0k(2.3m)(4.5m)(3.0m)13.5m

Interest Paid

21.0k31.0k12.0k30.0k60.0k69.0k153.0k238.0k79.0k135.0k

Income Taxes Paid

25.0k2.9m2.9m2.0m2.0m8.0k1.8m1.8m1.2m

Cyclacel Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

1.4 x